Triple-drug attack aims to stop melanoma from coming back

NCT ID NCT04722575

Ongoing Disease control Sponsor: Fondazione Melanoma Onlus Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether giving a mix of targeted drugs and immunotherapy before and after surgery can reduce the risk of melanoma returning in people with high-risk, resectable tumors. About 95 participants will receive vemurafenib, cobimetinib, and atezolizumab in different sequences. The main goal is to see if the cancer disappears completely in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vemurafenib, cobimetinib, and atezolizumab
What this could lead to: If successful, this combination could lower the chance of melanoma returning after surgery for people with high-risk disease.
What could go wrong: This is a mid-stage trial with only 95 participants, so results may not apply to everyone. Side effects from the drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori

Milan, Milano, 20133, Italy
IRCCS - Istituto Scientifico Romagnolo per la Cura e lo Studio dei Tumori (I.R.S.T) S.r.l.

Meldola, Forlì-Cesena, 47014, Italy
IRCCS San Martino - IST

Genova, 16132, Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale"

Naples, Naples, 80131, Italy
Istituto Oncologico Veneto

Padova, Padova, 35128, Italy
Ospedale S.M. Annunziata - Azienda USL Toscana Centro

Bagno a Ripoli, Firenze, 50012, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.